Literature DB >> 23733210

Cancer's true breakthroughs.

Elie Dolgin.   

Abstract

A new regulatory pathway established last year allows drugs with dramatic early clinical promise to be expedited to the market quicker than ever before. To date, most of these 'breakthrough' designations have gone to cancer agents, raising the prospect of faster access to the latest lifesaving therapies for the estimated 4,500 people newly diagnosed with cancer each day in the US. Elie Dolgin looks at what sets these breakthrough medicines apart.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733210     DOI: 10.1038/nm.3245

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  1 in total

1.  First 'breakthrough' drugs designated, but dilution worries linger.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

  1 in total
  5 in total

1.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Authors:  I S Nijhof; R W J Groen; H M Lokhorst; B van Kessel; A C Bloem; J van Velzen; R de Jong-Korlaar; H Yuan; W A Noort; S K Klein; A C M Martens; P Doshi; K Sasser; T Mutis; N W C J van de Donk
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

2.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

3.  Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Authors:  Iris Z Uras; Gina J Walter; Ruth Scheicher; Florian Bellutti; Michaela Prchal-Murphy; Anca S Tigan; Peter Valent; Florian H Heidel; Stefan Kubicek; Claudia Scholl; Stefan Fröhling; Veronika Sexl
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

4.  In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.

Authors:  Hui Zhang; Atish Patel; Shao-Lin Ma; Xiao Jie Li; Yun-Kai Zhang; Pei-Qi Yang; Rishil J Kathawala; Yi-Jun Wang; Nagaraju Anreddy; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

5.  Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Authors:  Theresa Placke; Katrin Faber; Atsushi Nonami; Sarah L Putwain; Helmut R Salih; Florian H Heidel; Alwin Krämer; David E Root; David A Barbie; Andrei V Krivtsov; Scott A Armstrong; William C Hahn; Brian J Huntly; Stephen M Sykes; Michael D Milsom; Claudia Scholl; Stefan Fröhling
Journal:  Blood       Date:  2014-04-24       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.